Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma
Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma
复制标题
DOI：
10.1093/jjco/hyaa070
复制
发表时间：
2020-08-01
影响因子：
2.4
通讯作者：
Takita, Junko
中科院分区：
文献类型：
--
作者：
Akazawa, Ryo;Umeda, Katsutsugu;Takita, Junko
复发性骨肉瘤患者的预后极差，最佳治疗仍有待确定。在这里，我们回顾性分析了9例复发性骨肉瘤患者用替莫唑胺/依托泊苷治疗的临床结果。在接受替莫唑胺/依托泊苷作为不可切除肿瘤的姑息疗法的两名患者中，一名患者保持存活，疾病稳定>4年。其余7例患者接受替莫唑胺/依托泊苷作为复发转移性疾病切除术后的辅助治疗;其中1例患者在41个月内无疾病。在三个O 6-甲基鸟嘌呤-DNA甲基转移酶蛋白阴性患者中的两个中观察到潜在的有益效果，而所有五个O 6-甲基鸟嘌呤-DNA甲基转移酶阳性患者随后复发。没有患者发生需要住院治疗的严重不良反应。替莫唑胺/足叶乙甙是治疗复发性骨肉瘤的一种可行的补救治疗方法。需要进一步的研究来验证O 6-甲基鸟嘌呤-DNA甲基转移酶蛋白表达作为预测对这种治疗的反应的生物标志物的效用。
The prognosis of patients with relapsed osteosarcoma is extremely poor and the optimal treatment remains to be identified. Here, we retrospectively analysed the clinical outcomes of nine patients with relapsed osteosarcoma treated with temozolomide/etoposide. Of the two patients who received temozolomide/etoposide as palliative therapy for unresectable tumours, one remained alive with stable disease for >4 years. The remaining seven patients received temozolomide/etoposide as adjuvant therapy following resection of relapsed metastatic disease; of these, one was free from disease for 41 months. Potentially beneficial effects were observed in two of three O6-methylguanine-DNA methyltransferase protein-negative patients, whereas all five O6-methylguani ne-DNA methyltransferase-positive patients experienced subsequent relapse. None of the patients experienced severe adverse effects requiring hospitalization. Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma. Further studies are needed to verify the utility of O6-methylguanine-DNA methyltransferase protein expression as a biomarker for predicting the response to this treatment.